110 related articles for article (PubMed ID: 12923565)
1. Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapy.
Ahmed A; Jevremovic D; Suzuki K; Kottke T; Thompson J; Emery S; Harrington K; Bateman A; Vile R
Gene Ther; 2003 Sep; 10(19):1663-71. PubMed ID: 12923565
[TBL] [Abstract][Full Text] [Related]
2. Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas.
Allen C; McDonald C; Giannini C; Peng KW; Rosales G; Russell SJ; Galanis E
J Gene Med; 2004 Nov; 6(11):1216-27. PubMed ID: 15459967
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic immune response induced by intratumoral expression of the fusogenic membrane protein of vesicular stomatitis virus and cytokines encoded by adenoviral vectors.
Hoffmann D; Bayer W; Wildner O
Int J Mol Med; 2007 Nov; 20(5):673-81. PubMed ID: 17912460
[TBL] [Abstract][Full Text] [Related]
4. Gene therapy for malignant glioma using Sindbis vectors expressing a fusogenic membrane glycoprotein.
Zhang J; Frolov I; Russell SJ
J Gene Med; 2004 Oct; 6(10):1082-91. PubMed ID: 15368589
[TBL] [Abstract][Full Text] [Related]
5. Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: implications for gene therapy.
Higuchi H; Bronk SF; Bateman A; Harrington K; Vile RG; Gores GJ
Cancer Res; 2000 Nov; 60(22):6396-402. PubMed ID: 11103804
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of hepatocellular carcinoma with a novel gene-viral therapeutic system CNHK300-murine endostatin].
Li GC; Nie MM; Yang JM; Su CQ; Sun LC; Qian YZ; Sham J; Fang GE; Wu MC; Qian QJ
Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):943-8. PubMed ID: 15329284
[TBL] [Abstract][Full Text] [Related]
7. Gene-viral vectors: a promising way to target tumor cells and express anticancer genes simultaneously.
Qian Q; Sham J; Che X; Xu J; Xue H; Cui Z; Zhu B; Wu M
Chin Med J (Engl); 2002 Aug; 115(8):1213-7. PubMed ID: 12215295
[TBL] [Abstract][Full Text] [Related]
8. Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction.
Johnson KJ; Peng KW; Allen C; Russell SJ; Galanis E
Gene Ther; 2003 May; 10(9):725-32. PubMed ID: 12704411
[TBL] [Abstract][Full Text] [Related]
9. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
Okada T; Caplen NJ; Ramsey WJ; Onodera M; Shimazaki K; Nomoto T; Ajalli R; Wildner O; Morris J; Kume A; Hamada H; Blaese RM; Ozawa K
J Gene Med; 2004 Mar; 6(3):288-99. PubMed ID: 15026990
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor.
Cho WK; Seong YR; Lee YH; Kim MJ; Hwang KS; Yoo J; Choi S; Jung CR; Im DS
Mol Ther; 2004 Nov; 10(5):938-49. PubMed ID: 15509511
[TBL] [Abstract][Full Text] [Related]
11. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
12. Enhanced antitumor effect of combined replicative adenovirus and nonreplicative adenovirus expressing interleukin-12 in an immunocompetent mouse model.
Nagayama Y; Nakao K; Mizuguchi H; Hayakawa T; Niwa M
Gene Ther; 2003 Aug; 10(16):1400-3. PubMed ID: 12883537
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with conditionally replicating adenovirus and replication defective adenovirus.
Lee CT; Park KH; Yanagisawa K; Adachi Y; Ohm JE; Nadaf S; Dikov MM; Curiel DT; Carbone DP
Cancer Res; 2004 Sep; 64(18):6660-5. PubMed ID: 15374981
[TBL] [Abstract][Full Text] [Related]
14. Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer.
Hoffmann D; Bangen JM; Bayer W; Wildner O
Gene Ther; 2006 Nov; 13(21):1534-44. PubMed ID: 16791286
[TBL] [Abstract][Full Text] [Related]
15. In vivo imaging of adenovirus transduction and enhanced therapeutic efficacy of combination therapy with conditionally replicating adenovirus and adenovirus-p27.
Lee CT; Lee YJ; Kwon SY; Lee J; Kim KI; Park KH; Kang JH; Yoo CG; Kim YW; Han SK; Chung JK; Shim YS; Curiel DT; Carbone DP
Cancer Res; 2006 Jan; 66(1):372-7. PubMed ID: 16397251
[TBL] [Abstract][Full Text] [Related]
16. Restricted expression of an adenoviral vector encoding Fas ligand (CD95L) enhances safety for cancer gene therapy.
Aoki K; Akyürek LM; San H; Leung K; Parmacek MS; Nabel EG; Nabel GJ
Mol Ther; 2000 Jun; 1(6):555-65. PubMed ID: 10933980
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapy.
Errington F; Bateman A; Kottke T; Thompson J; Harrington K; Merrick A; Hatfield P; Selby P; Vile R; Melcher A
Clin Cancer Res; 2006 Feb; 12(4):1333-41. PubMed ID: 16489091
[TBL] [Abstract][Full Text] [Related]
18. Trans-complementing adenoviral vectors for oncolytic therapy of malignant melanoma.
Wolkersdörfer GW; Morris JC; Ehninger G; Ramsey WJ
J Gene Med; 2004 Jun; 6(6):652-62. PubMed ID: 15170736
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression.
Kuppuswamy M; Spencer JF; Doronin K; Tollefson AE; Wold WS; Toth K
Gene Ther; 2005 Nov; 12(22):1608-17. PubMed ID: 16034456
[TBL] [Abstract][Full Text] [Related]
20. E1A RNA transcripts amplify adenovirus-mediated tumor reduction.
Dion LD; Goldsmith KT; Strong TV; Bilbao G; Curiel DT; Garver RI
Gene Ther; 1996 Nov; 3(11):1021-5. PubMed ID: 9044743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
